Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 10/2003

01-10-2003 | Original Paper

Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato(trans-R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles

Authors: C. F. Verschraegen, S. Kumagai, R. Davidson, B. Feig, P. Mansfield, S. J. Lee, D. S. Maclean, W. Hu, A. R. Khokhar, Z. H. Siddik

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2003

Login to get access

Abstract

Purpose

To perform a phase I study of intraperitoneal cis-bis-neodecanoato (trans-R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar vesicles (L-NDDP) for peritoneal carcinomatosis or sarcomatosis.

Methods

Eligible patients had normal renal, hematologic, and liver functions. Laparoscopy was performed on the first two courses for evaluation, adhesiolysis, and chemotherapy administration. Afterwards, chemotherapy was administered through a peritoneal catheter. Up to six courses were allowed. Peritoneal imaging with technetium-labeled sulfur colloid was used to determine adequate distribution prior to each course. Volunteering patients underwent pharmacokinetics studies during the second course.

Results

Fifteen of 16 registered patients, seven women and eight men (median age 53 years (range 26–76) and median performance status of 1) were assessable. Diagnoses were: malignant mesothelioma (six patients), signet ring cell (three), colon adenocarcinoma, pseudomyxoma peritonei, gastrointestinal stromal tumor (two each), and ovarian carcinoma (one). Median number of courses was two (range, one to six) Dose-limiting toxicity symptoms were fatigue and abdominal pain. Hematologic toxicities were minimal. Peri-operative complications included one colonic perforation requiring primary closure, a peritoneal catheter malfunction, a port site hematoma, and an ascites leak requiring re-suture. Five patients survived at least 3 years. Pharmacokinetics studies indicated a rapid but low absorption of drug into the systemic circulation, with a prolonged retention of platinum in the plasma compartment. Peritoneal L-NDDP exposure was 17 to 49-times greater than in the plasma compartment.

Conclusions

Peritoneal cavity exposure to L-NDDP is prolonged, and systemic absorption is limited, yielding a high peritoneal/plasmatic ratio. The recommended dose for phase II studies is 400 mg/m2 every 28 days.
Literature
1.
go back to reference Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T, Isawa E, Sumida M, Ohkubo H (1997) Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 79:884CrossRefPubMed Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T, Isawa E, Sumida M, Ohkubo H (1997) Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 79:884CrossRefPubMed
2.
go back to reference Griffiths CT, Fuller AF (1978) Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Surg Clin North Am 58:131PubMed Griffiths CT, Fuller AF (1978) Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Surg Clin North Am 58:131PubMed
3.
go back to reference Jacquet P, Stephens AD, Averbach AM, Chang D, Ettinghausen SE, Dalton RR, Steves MA, Sugarbaker PH (1996) Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 77:2622CrossRefPubMed Jacquet P, Stephens AD, Averbach AM, Chang D, Ettinghausen SE, Dalton RR, Steves MA, Sugarbaker PH (1996) Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 77:2622CrossRefPubMed
4.
go back to reference Sugarbaker PH, Zhu BW, Sese GB, Shmookler B (1993) Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum 36:323PubMed Sugarbaker PH, Zhu BW, Sese GB, Shmookler B (1993) Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum 36:323PubMed
5.
go back to reference Sugarbaker PH, Jablonski KA (1995) Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy (comments). Ann Surg 221:124PubMed Sugarbaker PH, Jablonski KA (1995) Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy (comments). Ann Surg 221:124PubMed
6.
go back to reference Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001PubMed Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001PubMed
7.
go back to reference Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer (comments). N Engl J Med 335:1950CrossRefPubMed Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer (comments). N Engl J Med 335:1950CrossRefPubMed
8.
go back to reference Armstrong DK, Bundy BN, Baergen R, Lele SB, Copeland LJ, Walker J, Burger R (2002) Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172). A803 Armstrong DK, Bundy BN, Baergen R, Lele SB, Copeland LJ, Walker J, Burger R (2002) Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172). A803
9.
go back to reference Fujimura T, Yonemura Y, Fushida S, Urade M, Takegawa S, Kamata T, Sugiyama K, Hasegawa H, Katayama K, Miwa K (1990) Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation. Cancer 65:65PubMed Fujimura T, Yonemura Y, Fushida S, Urade M, Takegawa S, Kamata T, Sugiyama K, Hasegawa H, Katayama K, Miwa K (1990) Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation. Cancer 65:65PubMed
10.
go back to reference Esquivel J, Vidal-Jove J, Steves MA, Sugarbaker PH (1993) Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy (comments). Surgery 113:631PubMed Esquivel J, Vidal-Jove J, Steves MA, Sugarbaker PH (1993) Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy (comments). Surgery 113:631PubMed
11.
go back to reference Perez-Soler R, Shin DM, Siddik ZH, Murphy WK, Huber M, Lee SJ, Khokhar AR, Hong WK (1997) Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Clin Cancer Res 3:373PubMed Perez-Soler R, Shin DM, Siddik ZH, Murphy WK, Huber M, Lee SJ, Khokhar AR, Hong WK (1997) Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Clin Cancer Res 3:373PubMed
12.
go back to reference Siddik ZH, Boxall FE, Harrap KR (1987) Flameless atomic absorption spectrophotometric determination of platinum in tissues solubilized in hyamine hydroxide. Anal Biochem 163:21PubMed Siddik ZH, Boxall FE, Harrap KR (1987) Flameless atomic absorption spectrophotometric determination of platinum in tissues solubilized in hyamine hydroxide. Anal Biochem 163:21PubMed
13.
go back to reference Perez-Soler R, Lopez-Berestein G, Lautersztain J, al-Baker S, Francis K, Macias-Kiger D, Raber MN, Khokhar AR (1990) Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(ii). Cancer Res 50:4254PubMed Perez-Soler R, Lopez-Berestein G, Lautersztain J, al-Baker S, Francis K, Macias-Kiger D, Raber MN, Khokhar AR (1990) Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(ii). Cancer Res 50:4254PubMed
14.
go back to reference Alberts DS, Markman M, Armstrong D, Rothenberg ML, Muggia F, Howell SB (2002) Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J Clin Oncol 20:3944 Alberts DS, Markman M, Armstrong D, Rothenberg ML, Muggia F, Howell SB (2002) Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J Clin Oncol 20:3944
15.
go back to reference Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T (1988) Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 61:232PubMed Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T (1988) Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 61:232PubMed
16.
go back to reference Hamazoe R, Maeta M, Kaibara N (1994) Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 73:2048PubMed Hamazoe R, Maeta M, Kaibara N (1994) Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 73:2048PubMed
17.
go back to reference Speyer JL (1985) The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies. Semin Oncol 12:23 Speyer JL (1985) The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies. Semin Oncol 12:23
18.
go back to reference Markman M (1994) Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer. Semin Oncol 21:17 Markman M (1994) Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer. Semin Oncol 21:17
19.
go back to reference Lind M, Murphy D, Sharma H, Tinker N, Smith A, McAuliffe C, Crowther D (1991) Comparative intraperitoneal pharmacokinetics of three platinum analogues. Cancer Chemother Pharmacol 28:315PubMed Lind M, Murphy D, Sharma H, Tinker N, Smith A, McAuliffe C, Crowther D (1991) Comparative intraperitoneal pharmacokinetics of three platinum analogues. Cancer Chemother Pharmacol 28:315PubMed
20.
go back to reference Elferink F, Vijgh WVD, Klein I, Huinink WTB, Dubbelman R, McVie J (1988) Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol 21:57PubMed Elferink F, Vijgh WVD, Klein I, Huinink WTB, Dubbelman R, McVie J (1988) Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol 21:57PubMed
21.
go back to reference Marchettini P, Stuart OA, Mohamed F, Yoo D, Sugarbaker PH (2002) Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. Cancer Chemother Pharmacol 49:499CrossRefPubMed Marchettini P, Stuart OA, Mohamed F, Yoo D, Sugarbaker PH (2002) Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. Cancer Chemother Pharmacol 49:499CrossRefPubMed
22.
go back to reference Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, Stoter G, Sparreboom A (2002) Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res 8:1237PubMed Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, Stoter G, Sparreboom A (2002) Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res 8:1237PubMed
23.
go back to reference Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M (1995) Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol 13:2961PubMed Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M (1995) Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol 13:2961PubMed
24.
go back to reference Perez-Soler R, Francis K, al-Baker S, Pilkiewicz F, Khokhar AR (1994) Preparation and characterization of liposomes containing a lipophilic cisplatin derivative for clinical use. J Microencapsul 11:41PubMed Perez-Soler R, Francis K, al-Baker S, Pilkiewicz F, Khokhar AR (1994) Preparation and characterization of liposomes containing a lipophilic cisplatin derivative for clinical use. J Microencapsul 11:41PubMed
25.
go back to reference Khokhar AR, al-Baker S, Brown T, Perez-Soler R (1991) Chemical and biological studies on a series of lipid-soluble (trans-(R,R)- and -(S,S)-1,2-diaminocyclohexane)platinum(II) complexes incorporated in liposomes. J Med Chem 34:325PubMed Khokhar AR, al-Baker S, Brown T, Perez-Soler R (1991) Chemical and biological studies on a series of lipid-soluble (trans-(R,R)- and -(S,S)-1,2-diaminocyclohexane)platinum(II) complexes incorporated in liposomes. J Med Chem 34:325PubMed
26.
go back to reference Perez-Soler R, Yang LY, Drewinko B, Lauterzstain J, Khokhar AR (1988) Increased cytotoxicity and reversal of resistance to cis-diamminedichloro-platinum(ii) with entrapment of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (ii) in multilamellar lipid vesicles. Cancer Res 48:4509PubMed Perez-Soler R, Yang LY, Drewinko B, Lauterzstain J, Khokhar AR (1988) Increased cytotoxicity and reversal of resistance to cis-diamminedichloro-platinum(ii) with entrapment of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (ii) in multilamellar lipid vesicles. Cancer Res 48:4509PubMed
27.
go back to reference Perez-Soler R, Lautersztain J, Stephens LC, Wright K, Khokhar AR (1989) Preclinical toxicity and pharmacology of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II). Cancer Chemother Pharmacol 24:1PubMed Perez-Soler R, Lautersztain J, Stephens LC, Wright K, Khokhar AR (1989) Preclinical toxicity and pharmacology of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II). Cancer Chemother Pharmacol 24:1PubMed
28.
go back to reference Yonemura Y, de Aretxabala X, Fujimura T, Fushida S, Katayama K, Bandou E, Sugiyama K, Kawamura T, Kinoshita K, Endou Y, Sasaki T (2001) Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepatogastroenterology 48:1776PubMed Yonemura Y, de Aretxabala X, Fujimura T, Fushida S, Katayama K, Bandou E, Sugiyama K, Kawamura T, Kinoshita K, Endou Y, Sasaki T (2001) Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepatogastroenterology 48:1776PubMed
29.
go back to reference Elias DM, Ouellet JF (2001) Intraperitoneal chemohyperthermia: rationale, technique, indications, and results. Surg Oncol Clin North Am 10:915 Elias DM, Ouellet JF (2001) Intraperitoneal chemohyperthermia: rationale, technique, indications, and results. Surg Oncol Clin North Am 10:915
Metadata
Title
Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato(trans-R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles
Authors
C. F. Verschraegen
S. Kumagai
R. Davidson
B. Feig
P. Mansfield
S. J. Lee
D. S. Maclean
W. Hu
A. R. Khokhar
Z. H. Siddik
Publication date
01-10-2003
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 10/2003
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-003-0481-3

Other articles of this Issue 10/2003

Journal of Cancer Research and Clinical Oncology 10/2003 Go to the issue